View ValuationChunbo 향후 성장Future 기준 점검 5/6Chunbo (는) 각각 연간 97% 및 28% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 110.2% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 4.2% 로 예상됩니다.핵심 정보97.0%이익 성장률110.23%EPS 성장률Chemicals 이익 성장63.6%매출 성장률28.0%향후 자기자본이익률4.15%애널리스트 커버리지Low마지막 업데이트19 May 2026최근 향후 성장 업데이트Major Estimate Revision • Apr 18Consensus estimates of losses per share improve by 37%The consensus outlook for earnings per share (EPS) in fiscal year 2026 has improved. 2026 revenue forecast increased from ₩186.7m to ₩189.0m. EPS estimate increased from -₩786 per share to -₩496 per share. Chemicals industry in South Korea expected to see average net income growth of 62% next year. Consensus price target of ₩74,667 unchanged from last update. Share price rose 22% to ₩66,000 over the past week.Price Target Changed • Jan 16Price target increased by 13% to ₩68,833Up from ₩60,857, the current price target is an average from 6 analysts. New target price is 44% above last closing price of ₩47,700. Stock is up 23% over the past year. The company is forecast to post a net loss per share of ₩636 next year compared to a net loss per share of ₩2,759 last year.Major Estimate Revision • Nov 18Consensus revenue estimates fall by 11%The consensus outlook for revenues in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from ₩153.1m to ₩135.9m. Forecast losses increased from -₩346 to -₩636 per share. Chemicals industry in South Korea expected to see average net income growth of 52% next year. Consensus price target up from ₩59,143 to ₩63,000. Share price fell 15% to ₩57,000 over the past week.Major Estimate Revision • Aug 20Consensus revenue estimates decrease by 12%, EPS upgradedThe consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from ₩173.8m to ₩153.1m. EPS estimate increased from -₩736 to -₩678 per share. Chemicals industry in South Korea expected to see average net income growth of 35% next year. Consensus price target broadly unchanged at ₩59,143. Share price fell 8.9% to ₩44,600 over the past week.Major Estimate Revision • May 16Consensus EPS estimates fall by 205%The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -₩259 to -₩790 per share. Revenue forecast unchanged at ₩175.4m. Chemicals industry in South Korea expected to see average net income growth of 34% next year. Consensus price target broadly unchanged at ₩55,125. Share price rose 2.9% to ₩34,950 over the past week.Major Estimate Revision • May 02Consensus EPS estimates fall by 545%, revenue upgradedThe consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast increased from ₩174.3m to ₩176.8m. Forecast EPS reduced from -₩40.19 to -₩259 per share. Chemicals industry in South Korea expected to see average net income growth of 35% next year. Consensus price target down from ₩57,875 to ₩55,375. Share price fell 3.8% to ₩35,750 over the past week.모든 업데이트 보기Recent updatesMajor Estimate Revision • Apr 18Consensus estimates of losses per share improve by 37%The consensus outlook for earnings per share (EPS) in fiscal year 2026 has improved. 2026 revenue forecast increased from ₩186.7m to ₩189.0m. EPS estimate increased from -₩786 per share to -₩496 per share. Chemicals industry in South Korea expected to see average net income growth of 62% next year. Consensus price target of ₩74,667 unchanged from last update. Share price rose 22% to ₩66,000 over the past week.Reported Earnings • Mar 13Full year 2025 earnings: EPS and revenues miss analyst expectationsFull year 2025 results: ₩5,752 loss per share (further deteriorated from ₩2,759 loss in FY 2024). Revenue: ₩133.8b (down 7.6% from FY 2024). Net loss: ₩57.8b (loss widened 111% from FY 2024). Revenue missed analyst estimates by 2.5%. Earnings per share (EPS) also missed analyst estimates significantly. Revenue is forecast to grow 40% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Chemicals industry in South Korea. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has fallen by 40% per year, which means it is performing significantly worse than earnings.공시 • Mar 07Chunbo Co., Ltd., Annual General Meeting, Mar 24, 2026Chunbo Co., Ltd., Annual General Meeting, Mar 24, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 312, jungwonsaneop-ro, judeok-eup, chungcheongbuk-do, chungju South KoreaNew Risk • Mar 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.5x net interest cover). Earnings are forecast to decline by an average of 52% per year for the foreseeable future. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (20% increase in shares outstanding).Valuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 26%After last week's 26% share price decline to ₩40,500, the stock trades at a trailing P/E ratio of 30.7x. Average forward P/E is 14x in the Chemicals industry in South Korea. Total loss to shareholders of 85% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩62,042 per share.Buy Or Sell Opportunity • Mar 03Now 26% undervalued after recent price dropOver the last 90 days, the stock has fallen 15% to ₩49,000. The fair value is estimated to be ₩66,238, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 35% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 104% in 2 years. Earnings are forecast to decline by 132% in the next 2 years.Buy Or Sell Opportunity • Feb 13Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 22% to ₩51,100. The fair value is estimated to be ₩64,568, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 35% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 104% in 2 years. Earnings are forecast to decline by 132% in the next 2 years.분석 기사 • Feb 08What Does Chunbo Co., Ltd.'s (KOSDAQ:278280) Share Price Indicate?Chunbo Co., Ltd. ( KOSDAQ:278280 ), is not the largest company out there, but it received a lot of attention from a...Valuation Update With 7 Day Price Move • Jan 28Investor sentiment improves as stock rises 25%After last week's 25% share price gain to ₩61,000, the stock trades at a trailing P/E ratio of 45.3x. Average forward P/E is 12x in the Chemicals industry in South Korea. Total loss to shareholders of 75% over the past three years.분석 기사 • Jan 24Is Chunbo (KOSDAQ:278280) Using Too Much Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Price Target Changed • Jan 16Price target increased by 13% to ₩68,833Up from ₩60,857, the current price target is an average from 6 analysts. New target price is 44% above last closing price of ₩47,700. Stock is up 23% over the past year. The company is forecast to post a net loss per share of ₩636 next year compared to a net loss per share of ₩2,759 last year.New Risk • Jan 09New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 17% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.5x net interest cover). Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings are forecast to decline by an average of 102% per year for the foreseeable future. Minor Risk Shareholders have been diluted in the past year (17% increase in shares outstanding).분석 기사 • Jan 09Chunbo Co., Ltd. (KOSDAQ:278280) Shares Slammed 28% But Getting In Cheap Might Be Difficult RegardlessChunbo Co., Ltd. ( KOSDAQ:278280 ) shares have retraced a considerable 28% in the last month, reversing a fair amount...Valuation Update With 7 Day Price Move • Dec 09Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩68,000, the stock trades at a trailing P/E ratio of 43.2x. Average forward P/E is 11x in the Chemicals industry in South Korea. Total loss to shareholders of 71% over the past three years.Valuation Update With 7 Day Price Move • Nov 19Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₩55,300, the stock trades at a trailing P/E ratio of 39.6x. Average forward P/E is 12x in the Chemicals industry in South Korea. Total loss to shareholders of 76% over the past three years.Major Estimate Revision • Nov 18Consensus revenue estimates fall by 11%The consensus outlook for revenues in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from ₩153.1m to ₩135.9m. Forecast losses increased from -₩346 to -₩636 per share. Chemicals industry in South Korea expected to see average net income growth of 52% next year. Consensus price target up from ₩59,143 to ₩63,000. Share price fell 15% to ₩57,000 over the past week.분석 기사 • Oct 17Chunbo Co., Ltd.'s (KOSDAQ:278280) 34% Jump Shows Its Popularity With InvestorsChunbo Co., Ltd. ( KOSDAQ:278280 ) shares have continued their recent momentum with a 34% gain in the last month alone...Valuation Update With 7 Day Price Move • Oct 17Investor sentiment improves as stock rises 40%After last week's 40% share price gain to ₩59,600, the stock trades at a trailing P/E ratio of 42.7x. Average forward P/E is 11x in the Chemicals industry in South Korea. Total loss to shareholders of 72% over the past three years.분석 기사 • Oct 16Returns On Capital Signal Tricky Times Ahead For Chunbo (KOSDAQ:278280)Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Ideally, a business...New Risk • Oct 16New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.5x net interest cover). Earnings are forecast to decline by an average of 116% per year for the foreseeable future. Minor Risk Share price has been volatile over the past 3 months (7.7% average weekly change).분석 기사 • Aug 27We Like Chunbo's (KOSDAQ:278280) Earnings For More Than Just Statutory ProfitChunbo Co., Ltd.'s ( KOSDAQ:278280 ) recent earnings report didn't offer any surprises, with the shares unchanged over...New Risk • Aug 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.4x net interest cover). Earnings are forecast to decline by an average of 35% per year for the foreseeable future. Minor Risk Share price has been volatile over the past 3 months (7.8% average weekly change).Major Estimate Revision • Aug 20Consensus revenue estimates decrease by 12%, EPS upgradedThe consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from ₩173.8m to ₩153.1m. EPS estimate increased from -₩736 to -₩678 per share. Chemicals industry in South Korea expected to see average net income growth of 35% next year. Consensus price target broadly unchanged at ₩59,143. Share price fell 8.9% to ₩44,600 over the past week.분석 기사 • Jul 21Does Chunbo (KOSDAQ:278280) Have A Healthy Balance Sheet?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...분석 기사 • Jun 24After Leaping 30% Chunbo Co., Ltd. (KOSDAQ:278280) Shares Are Not Flying Under The RadarChunbo Co., Ltd. ( KOSDAQ:278280 ) shareholders would be excited to see that the share price has had a great month...분석 기사 • May 30Returns On Capital At Chunbo (KOSDAQ:278280) Paint A Concerning PictureWhat are the early trends we should look for to identify a stock that could multiply in value over the long term...New Risk • May 23New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 22% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.4x net interest cover). Earnings are forecast to decline by an average of 22% per year for the foreseeable future.Major Estimate Revision • May 16Consensus EPS estimates fall by 205%The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -₩259 to -₩790 per share. Revenue forecast unchanged at ₩175.4m. Chemicals industry in South Korea expected to see average net income growth of 34% next year. Consensus price target broadly unchanged at ₩55,125. Share price rose 2.9% to ₩34,950 over the past week.Major Estimate Revision • May 02Consensus EPS estimates fall by 545%, revenue upgradedThe consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast increased from ₩174.3m to ₩176.8m. Forecast EPS reduced from -₩40.19 to -₩259 per share. Chemicals industry in South Korea expected to see average net income growth of 35% next year. Consensus price target down from ₩57,875 to ₩55,375. Share price fell 3.8% to ₩35,750 over the past week.Price Target Changed • May 01Price target decreased by 9.4% to ₩55,375Down from ₩61,125, the current price target is an average from 8 analysts. New target price is 53% above last closing price of ₩36,200. Stock is down 53% over the past year. The company is forecast to post a net loss per share of ₩259 next year compared to a net loss per share of ₩2,759 last year.Major Estimate Revision • Apr 09Consensus revenue estimates decrease by 16%The consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from ₩207.8m to ₩174.3m. EPS estimate unchanged from -₩40.19 per share at last update. Chemicals industry in South Korea expected to see average net income growth of 31% next year. Consensus price target down from ₩65,375 to ₩63,857. Share price fell 7.3% to ₩30,300 over the past week.Major Estimate Revision • Apr 03Consensus EPS estimates fall by 64%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from ₩207.8m to ₩189.6m. Losses expected to increase from ₩389 per share to ₩640. Chemicals industry in South Korea expected to see average net income growth of 31% next year. Consensus price target down from ₩65,375 to ₩61,125. Share price fell 11% to ₩31,500 over the past week.Major Estimate Revision • Mar 21Consensus EPS estimates upgraded to ₩389 loss, revenue downgradedThe consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from ₩229.2m to ₩207.8m. 2025 losses expected to reduce from -₩542 to -₩389 per share. Chemicals industry in South Korea expected to see average net income growth of 28% next year. Consensus price target broadly unchanged at ₩66,444. Share price rose 3.1% to ₩37,800 over the past week.Reported Earnings • Mar 13Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2024 results: ₩2,759 loss per share (improved from ₩4,205 loss in FY 2023). Revenue: ₩144.9b (down 21% from FY 2023). Net loss: ₩27.4b (loss narrowed 34% from FY 2023). Revenue missed analyst estimates by 6.6%. Earnings per share (EPS) exceeded analyst estimates by 46%. Revenue is forecast to grow 47% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Chemicals industry in South Korea. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 50 percentage points per year, which is a significant difference in performance.공시 • Mar 06Chunbo Co., Ltd., Annual General Meeting, Mar 20, 2025Chunbo Co., Ltd., Annual General Meeting, Mar 20, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 312, jungwonsaneop-ro, judeok-eup, chungcheongbuk-do, chungju South Korea공시 • Nov 30Chunbo Co., Ltd. announced that it has received KRW 200 billion in funding from a group of investorsOn November 29, 2024 Chunbo Co., Ltd. closed the transaction.Major Estimate Revision • Nov 16Consensus EPS estimates upgraded to ₩5,074 loss, revenue downgradedThe consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from ₩173.9m to ₩157.3m. 2024 losses expected to reduce from -₩5,968 to -₩5,074 per share. Chemicals industry in South Korea expected to see average net income growth of 35% next year. Consensus price target down from ₩78,222 to ₩69,667. Share price fell 26% to ₩36,900 over the past week.분석 기사 • Nov 13Why We're Not Concerned Yet About Chunbo Co., Ltd.'s (KOSDAQ:278280) 26% Share Price PlungeChunbo Co., Ltd. ( KOSDAQ:278280 ) shareholders that were waiting for something to happen have been dealt a blow with a...Major Estimate Revision • Oct 15Consensus EPS estimates fall by 75%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from ₩177.7m to ₩173.9m. Losses expected to increase from ₩3,404 per share to ₩5,968. Chemicals industry in South Korea expected to see average net income growth of 55% next year. Consensus price target down from ₩80,778 to ₩78,222. Share price fell 9.3% to ₩58,500 over the past week.Major Estimate Revision • Sep 05Consensus EPS estimates fall by 13%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from ₩181.7m to ₩175.9m. Losses expected to increase from ₩3,151 per share to ₩3,556. Chemicals industry in South Korea expected to see average net income growth of 63% next year. Consensus price target down from ₩83,000 to ₩80,778. Share price was steady at ₩58,700 over the past week.Reported Earnings • Aug 16Second quarter 2024 earnings released: ₩2,196 loss per share (vs ₩3,107 loss in 2Q 2023)Second quarter 2024 results: ₩2,196 loss per share (improved from ₩3,107 loss in 2Q 2023). Revenue: ₩35.9b (down 24% from 2Q 2023). Net loss: ₩21.8b (loss narrowed 29% from 2Q 2023). Revenue is forecast to grow 35% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in South Korea. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 58 percentage points per year, which is a significant difference in performance.분석 기사 • Aug 15What You Can Learn From Chunbo Co., Ltd.'s (KOSDAQ:278280) P/SChunbo Co., Ltd.'s ( KOSDAQ:278280 ) price-to-sales (or "P/S") ratio of 3.6x may look like a poor investment...분석 기사 • Jul 16Would Chunbo (KOSDAQ:278280) Be Better Off With Less Debt?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Price Target Changed • Jun 21Price target decreased by 18% to ₩98,800Down from ₩119,917, the current price target is an average from 10 analysts. New target price is 36% above last closing price of ₩72,700. Stock is down 63% over the past year. The company is forecast to post a net loss per share of ₩3,408 next year compared to a net loss per share of ₩4,205 last year.Major Estimate Revision • May 30Consensus revenue estimates decrease by 11%The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from ₩228.0m to ₩204.0m. EPS estimate unchanged from -₩3,544 per share at last update. Chemicals industry in South Korea expected to see average net income growth of 78% next year. Consensus price target down from ₩129,083 to ₩119,917. Share price fell 5.5% to ₩71,700 over the past week.Price Target Changed • May 25Price target decreased by 7.9% to ₩123,250Down from ₩133,833, the current price target is an average from 12 analysts. New target price is 70% above last closing price of ₩72,700. Stock is down 61% over the past year. The company is forecast to post a net loss per share of ₩2,724 next year compared to a net loss per share of ₩4,205 last year.분석 기사 • Apr 17Is Chunbo (KOSDAQ:278280) Using Too Much Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Reported Earnings • Mar 15Full year 2023 earnings released: ₩4,205 loss per share (vs ₩3,763 profit in FY 2022)Full year 2023 results: ₩4,205 loss per share (down from ₩3,763 profit in FY 2022). Revenue: ₩182.7b (down 44% from FY 2022). Net loss: ₩41.8b (down 212% from profit in FY 2022). Revenue is forecast to grow 45% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Chemicals industry in South Korea. Over the last 3 years on average, earnings per share has fallen by 57% per year but the company’s share price has only fallen by 19% per year, which means it has not declined as severely as earnings.New Risk • Mar 15New major risk - Revenue and earnings growthEarnings have declined by 6.0% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.7x net interest cover). Earnings have declined by 6.0% per year over the past 5 years.Price Target Changed • Feb 22Price target decreased by 8.6% to ₩143,538Down from ₩157,077, the current price target is an average from 13 analysts. New target price is 47% above last closing price of ₩97,700. Stock is down 58% over the past year. The company is forecast to post a net loss per share of ₩2,706 compared to earnings per share of ₩3,763 last year.Upcoming Dividend • Dec 20Upcoming dividend of ₩500 per share at 0.4% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 10 April 2024. The company is not currently making a profit and is not cash flow positive. Trailing yield: 0.4%. Lower than top quartile of South Korean dividend payers (3.5%). Lower than average of industry peers (1.8%).Price Target Changed • Nov 14Price target decreased by 8.4% to ₩199,083Down from ₩217,333, the current price target is an average from 12 analysts. New target price is 102% above last closing price of ₩98,500. Stock is down 62% over the past year. The company is forecast to post a net loss per share of ₩910 compared to earnings per share of ₩3,763 last year.New Risk • Nov 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (16% operating cash flow to total debt). Minor Risk Share price has been volatile over the past 3 months (9.0% average weekly change).Price Target Changed • Oct 24Price target decreased by 13% to ₩224,833Down from ₩258,583, the current price target is an average from 12 analysts. New target price is 102% above last closing price of ₩111,400. Stock is down 48% over the past year. The company is forecast to post earnings per share of ₩829 for next year compared to ₩3,763 last year.Price Target Changed • Sep 02Price target decreased by 7.5% to ₩275,250Down from ₩297,545, the current price target is an average from 12 analysts. New target price is 85% above last closing price of ₩148,700. Stock is down 32% over the past year. The company is forecast to post earnings per share of ₩2,592 for next year compared to ₩3,763 last year.Major Estimate Revision • Aug 17Consensus revenue estimates fall by 10%The consensus outlook for revenues in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from ₩299.0m to ₩267.7m. EPS estimate fell from ₩2,562 to ₩1,832 per share. Net income forecast to grow 17% next year vs 17% growth forecast for Chemicals industry in South Korea. Consensus price target down from ₩297,545 to ₩285,727. Share price fell 15% to ₩147,900 over the past week.Valuation Update With 7 Day Price Move • Aug 16Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ₩138,500, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 13x in the Chemicals industry in South Korea. Total returns to shareholders of 11% over the past three years.Major Estimate Revision • Jul 22Consensus EPS estimates fall by 16%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from ₩320.4m to ₩312.6m. EPS estimate also fell from ₩3,330 per share to ₩2,810 per share. Net income forecast to grow 51% next year vs 38% growth forecast for Chemicals industry in South Korea. Consensus price target of ₩297,545 unchanged from last update. Share price rose 6.1% to ₩198,000 over the past week.Major Estimate Revision • May 02Consensus revenue estimates decrease by 27%The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from ₩432.8m to ₩317.6m. EPS estimate unchanged from ₩3,578 per share at last update. Chemicals industry in South Korea expected to see average net income growth of 23% next year. Consensus price target down from ₩326,636 to ₩317,545. Share price was steady at ₩193,700 over the past week.Valuation Update With 7 Day Price Move • Apr 25Investor sentiment deteriorates as stock falls 23%After last week's 23% share price decline to ₩195,000, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 11x in the Chemicals industry in South Korea. Total returns to shareholders of 200% over the past three years.Major Estimate Revision • Apr 13Consensus EPS estimates increase by 11%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has improved. 2023 revenue forecast increased from ₩407.0m to ₩432.8m. EPS estimate increased from ₩5,389 to ₩5,970 per share. Net income forecast to grow 65% next year vs 33% growth forecast for Chemicals industry in South Korea. Consensus price target up from ₩315,300 to ₩326,636. Share price rose 3.0% to ₩261,000 over the past week.Major Estimate Revision • Mar 15Consensus revenue estimates fall by 20%The consensus outlook for revenues in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from ₩507.9m to ₩407.5m. EPS estimate fell from ₩7,701 to ₩4,928 per share. Net income forecast to grow 39% next year vs 30% growth forecast for Chemicals industry in South Korea. Consensus price target broadly unchanged at ₩315,300. Share price fell 14% to ₩226,500 over the past week.Upcoming Dividend • Dec 21Upcoming dividend of ₩500 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 10 April 2023. Payout ratio is a comfortable 5.3% but the company is not cash flow positive. Trailing yield: 0.1%. Lower than top quartile of South Korean dividend payers (3.3%). Lower than average of industry peers (2.4%).Price Target Changed • Sep 09Price target decreased to ₩360,000Down from ₩396,667, the current price target is an average from 9 analysts. New target price is 62% above last closing price of ₩222,900. Stock is down 16% over the past year. The company is forecast to post earnings per share of ₩4,791 for next year compared to ₩4,438 last year.Valuation Update With 7 Day Price Move • May 19Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₩283,200, the stock trades at a forward P/E ratio of 50x. Average forward P/E is 12x in the Chemicals industry in South Korea. Total returns to shareholders of 283% over the past three years.Reported Earnings • Mar 19Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2021 results: EPS: ₩4,438 (up from ₩2,767 in FY 2020). Revenue: ₩271.6b (up 75% from FY 2020). Net income: ₩43.8b (up 60% from FY 2020). Profit margin: 16% (down from 18% in FY 2020). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 2.5%. Earnings per share (EPS) missed analyst estimates by 100%. Over the next year, revenue is forecast to grow 45%, compared to a 19% growth forecast for the industry in South Korea. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 60% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Jan 27Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩262,500, the stock trades at a forward P/E ratio of 44x. Average forward P/E is 10x in the Chemicals industry in South Korea. Total returns to shareholders of 42% over the past year.Upcoming Dividend • Dec 22Upcoming dividend of ₩300 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 11 April 2022. Payout ratio is a comfortable 7.5% but the company is not cash flow positive. Trailing yield: 0.1%. Lower than top quartile of South Korean dividend payers (2.4%). Lower than average of industry peers (1.4%).Valuation Update With 7 Day Price Move • Sep 08Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₩265,500, the stock trades at a forward P/E ratio of 51x. Average forward P/E is 13x in the Chemicals industry in South Korea. Total returns to shareholders of 72% over the past year. Simply Wall St's valuation model estimates the intrinsic value at ₩137,141 per share.Price Target Changed • Aug 22Price target increased to ₩296,429Up from ₩270,714, the current price target is an average from 7 analysts. New target price is 24% above last closing price of ₩238,900. Stock is up 63% over the past year.Price Target Changed • Jul 20Price target increased to ₩266,429Up from ₩243,889, the current price target is an average from 7 analysts. New target price is 19% above last closing price of ₩223,100. Stock is up 137% over the past year.Valuation Update With 7 Day Price Move • Jul 09Investor sentiment improved over the past weekAfter last week's 20% share price gain to ₩217,500, the stock trades at a forward P/E ratio of 47x. Average forward P/E is 11x in the Chemicals industry in South Korea. Total returns to shareholders of 119% over the past year. Simply Wall St's valuation model estimates the intrinsic value at ₩279,646 per share.Price Target Changed • Jul 08Price target increased to ₩260,714Up from ₩237,222, the current price target is an average from 8 analysts. New target price is 27% above last closing price of ₩205,500. Stock is up 106% over the past year.분석 기사 • Apr 14Is Chunbo (KOSDAQ:278280) Using Too Much Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...분석 기사 • Mar 16Does Chunbo (KOSDAQ:278280) Deserve A Spot On Your Watchlist?Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling...Reported Earnings • Mar 11Full year 2020 earnings released: EPS ₩2,742 (vs ₩2,348 in FY 2019)The company reported a solid full year result with improved earnings and revenues, although profit margins were flat. Full year 2020 results: Revenue: ₩155.5b (up 15% from FY 2019). Net income: ₩27.3b (up 19% from FY 2019). Profit margin: 18% (in line with FY 2019).분석 기사 • Mar 02Is It Time To Consider Buying Chunbo Co., Ltd. (KOSDAQ:278280)?While Chunbo Co., Ltd. ( KOSDAQ:278280 ) might not be the most widely known stock at the moment, it saw significant...Is New 90 Day High Low • Feb 26New 90-day low: ₩160,200The company is down 11% from its price of ₩180,300 on 27 November 2020. The South Korean market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩139,545 per share.분석 기사 • Feb 17Has Chunbo (KOSDAQ:278280) Got What It Takes To Become A Multi-Bagger?What trends should we look for it we want to identify stocks that can multiply in value over the long term? Firstly...분석 기사 • Feb 02Should We Be Delighted With Chunbo Co., Ltd.'s (KOSDAQ:278280) ROE Of 11%?Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...분석 기사 • Jan 18Introducing Chunbo (KOSDAQ:278280), The Stock That Zoomed 166% In The Last YearChunbo Co., Ltd. ( KOSDAQ:278280 ) shareholders might be concerned after seeing the share price drop 10% in the last...Price Target Changed • Jan 07Price target raised to ₩204,250Up from ₩184,400, the current price target is an average from 8 analysts. The new target price is 8.1% above the current share price of ₩189,000. As of last close, the stock is up 194% over the past year.Is New 90 Day High Low • Jan 04New 90-day high: ₩191,700The company is up 13% from its price of ₩169,100 on 06 October 2020. The South Korean market is up 21% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 22% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩139,908 per share.분석 기사 • Dec 31Is Chunbo Co., Ltd. (KOSDAQ:278280) Worth ₩182k Based On Its Intrinsic Value?Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Chunbo Co., Ltd...분석 기사 • Dec 16Here's Why We Don't Think Chunbo's (KOSDAQ:278280) Statutory Earnings Reflect Its Underlying Earnings PotentialBroadly speaking, profitable businesses are less risky than unprofitable ones. However, sometimes companies receive a...Price Target Changed • Dec 15Price target raised to ₩184,400Up from ₩154,333, the current price target is an average from 11 analysts. The new target price is 7.8% above the current share price of ₩171,000. As of last close, the stock is up 215% over the past year.분석 기사 • Dec 02Is Chunbo (KOSDAQ:278280) A Risky Investment?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...분석 기사 • Nov 18Will Chunbo (KOSDAQ:278280) Multiply In Value Going Forward?What trends should we look for it we want to identify stocks that can multiply in value over the long term? Firstly...Valuation Update With 7 Day Price Move • Nov 03Market bids up stock over the past weekAfter last week's 18% share price gain to ₩164,400, the stock is trading at a trailing P/E ratio of 74.6x, up from the previous P/E ratio of 63.2x. This compares to an average P/E of 12x in the Chemicals industry in South Korea. Total returns to shareholders over the past year are 155%.이익 및 매출 성장 예측KOSDAQ:A278280 - 애널리스트 향후 추정치 및 과거 재무 데이터 (KRW Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/2028308,5234,50034,00079,000312/31/2027292,05612,50044,66743,000512/31/2026192,562-19,00016,00040,000412/31/2025133,850-57,774-13,5728,033N/A9/30/2025130,95915,644-10,76521,684N/A6/30/2025137,87813,861-31,08027,647N/A3/31/2025140,719-2,863-76,23221,284N/A12/31/2024144,913-27,397-106,68522,485N/A9/30/2024152,269-60,168-134,07924,681N/A6/30/2024164,086-60,554-154,67028,217N/A3/31/2024175,450-69,596-185,20060,509N/A12/31/2023182,698-41,752-249,42657,160N/A9/30/2023227,804-36,327-285,44561,771N/A6/30/2023263,058-14,377-267,94869,896N/A3/31/2023281,57529,461-199,39658,760N/A12/31/2022328,85937,363-132,31865,570N/A9/30/2022332,95056,645-77,31768,042N/A6/30/2022322,15951,411-99,57613,375N/A3/31/2022316,78946,490-112,241-18,791N/A12/31/2021271,57943,770-84,964-14,279N/A9/30/2021228,37539,572-80,096-28,450N/A6/30/2021192,81133,570-47,3165,304N/A3/31/2021166,07330,479-36,31022,908N/A12/31/2020155,49127,344-31,94619,059N/A9/30/2020144,12722,806-19,99322,440N/A6/30/2020140,45422,039-3,54431,575N/A3/31/2020140,19423,0428,49135,910N/A12/31/2019135,31123,045-2,41822,697N/A9/30/2019138,10524,900N/A26,465N/A6/30/2019133,54026,799N/A21,909N/A3/31/2019127,96124,500N/A13,270N/A12/31/2018120,08922,635N/A22,194N/A9/30/2018104,47218,262N/A16,953N/A6/30/2018100,52017,335N/A15,178N/A3/31/201892,93916,448N/A14,651N/A12/31/201787,48614,824N/A14,335N/A12/31/201671,96012,565N/A7,733N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: A278280 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률(3.1%)보다 빠른 성장으로 간주됩니다.수익 vs 시장: A278280 (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.고성장 수익: A278280 향후 3년 내에 수익을 낼 것으로 예상됩니다.수익 대 시장: A278280 의 수익(연간 28%)이 KR 시장(연간 16.5%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: A278280 의 수익(연간 28%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: A278280의 자본 수익률은 3년 후 4.2%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YMaterials 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/23 12:29종가2026/05/22 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Chunbo Co., Ltd.는 11명의 분석가가 다루고 있습니다. 이 중 5명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Sung Hwan KimBookook Securities Co. LtdHyun-hee JungDaiwa Securities Co. Ltd.null nullDBS Bank Ltd8명의 분석가 더 보기
Major Estimate Revision • Apr 18Consensus estimates of losses per share improve by 37%The consensus outlook for earnings per share (EPS) in fiscal year 2026 has improved. 2026 revenue forecast increased from ₩186.7m to ₩189.0m. EPS estimate increased from -₩786 per share to -₩496 per share. Chemicals industry in South Korea expected to see average net income growth of 62% next year. Consensus price target of ₩74,667 unchanged from last update. Share price rose 22% to ₩66,000 over the past week.
Price Target Changed • Jan 16Price target increased by 13% to ₩68,833Up from ₩60,857, the current price target is an average from 6 analysts. New target price is 44% above last closing price of ₩47,700. Stock is up 23% over the past year. The company is forecast to post a net loss per share of ₩636 next year compared to a net loss per share of ₩2,759 last year.
Major Estimate Revision • Nov 18Consensus revenue estimates fall by 11%The consensus outlook for revenues in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from ₩153.1m to ₩135.9m. Forecast losses increased from -₩346 to -₩636 per share. Chemicals industry in South Korea expected to see average net income growth of 52% next year. Consensus price target up from ₩59,143 to ₩63,000. Share price fell 15% to ₩57,000 over the past week.
Major Estimate Revision • Aug 20Consensus revenue estimates decrease by 12%, EPS upgradedThe consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from ₩173.8m to ₩153.1m. EPS estimate increased from -₩736 to -₩678 per share. Chemicals industry in South Korea expected to see average net income growth of 35% next year. Consensus price target broadly unchanged at ₩59,143. Share price fell 8.9% to ₩44,600 over the past week.
Major Estimate Revision • May 16Consensus EPS estimates fall by 205%The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -₩259 to -₩790 per share. Revenue forecast unchanged at ₩175.4m. Chemicals industry in South Korea expected to see average net income growth of 34% next year. Consensus price target broadly unchanged at ₩55,125. Share price rose 2.9% to ₩34,950 over the past week.
Major Estimate Revision • May 02Consensus EPS estimates fall by 545%, revenue upgradedThe consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast increased from ₩174.3m to ₩176.8m. Forecast EPS reduced from -₩40.19 to -₩259 per share. Chemicals industry in South Korea expected to see average net income growth of 35% next year. Consensus price target down from ₩57,875 to ₩55,375. Share price fell 3.8% to ₩35,750 over the past week.
Major Estimate Revision • Apr 18Consensus estimates of losses per share improve by 37%The consensus outlook for earnings per share (EPS) in fiscal year 2026 has improved. 2026 revenue forecast increased from ₩186.7m to ₩189.0m. EPS estimate increased from -₩786 per share to -₩496 per share. Chemicals industry in South Korea expected to see average net income growth of 62% next year. Consensus price target of ₩74,667 unchanged from last update. Share price rose 22% to ₩66,000 over the past week.
Reported Earnings • Mar 13Full year 2025 earnings: EPS and revenues miss analyst expectationsFull year 2025 results: ₩5,752 loss per share (further deteriorated from ₩2,759 loss in FY 2024). Revenue: ₩133.8b (down 7.6% from FY 2024). Net loss: ₩57.8b (loss widened 111% from FY 2024). Revenue missed analyst estimates by 2.5%. Earnings per share (EPS) also missed analyst estimates significantly. Revenue is forecast to grow 40% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Chemicals industry in South Korea. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has fallen by 40% per year, which means it is performing significantly worse than earnings.
공시 • Mar 07Chunbo Co., Ltd., Annual General Meeting, Mar 24, 2026Chunbo Co., Ltd., Annual General Meeting, Mar 24, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 312, jungwonsaneop-ro, judeok-eup, chungcheongbuk-do, chungju South Korea
New Risk • Mar 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.5x net interest cover). Earnings are forecast to decline by an average of 52% per year for the foreseeable future. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (20% increase in shares outstanding).
Valuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 26%After last week's 26% share price decline to ₩40,500, the stock trades at a trailing P/E ratio of 30.7x. Average forward P/E is 14x in the Chemicals industry in South Korea. Total loss to shareholders of 85% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩62,042 per share.
Buy Or Sell Opportunity • Mar 03Now 26% undervalued after recent price dropOver the last 90 days, the stock has fallen 15% to ₩49,000. The fair value is estimated to be ₩66,238, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 35% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 104% in 2 years. Earnings are forecast to decline by 132% in the next 2 years.
Buy Or Sell Opportunity • Feb 13Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 22% to ₩51,100. The fair value is estimated to be ₩64,568, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 35% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 104% in 2 years. Earnings are forecast to decline by 132% in the next 2 years.
분석 기사 • Feb 08What Does Chunbo Co., Ltd.'s (KOSDAQ:278280) Share Price Indicate?Chunbo Co., Ltd. ( KOSDAQ:278280 ), is not the largest company out there, but it received a lot of attention from a...
Valuation Update With 7 Day Price Move • Jan 28Investor sentiment improves as stock rises 25%After last week's 25% share price gain to ₩61,000, the stock trades at a trailing P/E ratio of 45.3x. Average forward P/E is 12x in the Chemicals industry in South Korea. Total loss to shareholders of 75% over the past three years.
분석 기사 • Jan 24Is Chunbo (KOSDAQ:278280) Using Too Much Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Price Target Changed • Jan 16Price target increased by 13% to ₩68,833Up from ₩60,857, the current price target is an average from 6 analysts. New target price is 44% above last closing price of ₩47,700. Stock is up 23% over the past year. The company is forecast to post a net loss per share of ₩636 next year compared to a net loss per share of ₩2,759 last year.
New Risk • Jan 09New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 17% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.5x net interest cover). Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings are forecast to decline by an average of 102% per year for the foreseeable future. Minor Risk Shareholders have been diluted in the past year (17% increase in shares outstanding).
분석 기사 • Jan 09Chunbo Co., Ltd. (KOSDAQ:278280) Shares Slammed 28% But Getting In Cheap Might Be Difficult RegardlessChunbo Co., Ltd. ( KOSDAQ:278280 ) shares have retraced a considerable 28% in the last month, reversing a fair amount...
Valuation Update With 7 Day Price Move • Dec 09Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩68,000, the stock trades at a trailing P/E ratio of 43.2x. Average forward P/E is 11x in the Chemicals industry in South Korea. Total loss to shareholders of 71% over the past three years.
Valuation Update With 7 Day Price Move • Nov 19Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₩55,300, the stock trades at a trailing P/E ratio of 39.6x. Average forward P/E is 12x in the Chemicals industry in South Korea. Total loss to shareholders of 76% over the past three years.
Major Estimate Revision • Nov 18Consensus revenue estimates fall by 11%The consensus outlook for revenues in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from ₩153.1m to ₩135.9m. Forecast losses increased from -₩346 to -₩636 per share. Chemicals industry in South Korea expected to see average net income growth of 52% next year. Consensus price target up from ₩59,143 to ₩63,000. Share price fell 15% to ₩57,000 over the past week.
분석 기사 • Oct 17Chunbo Co., Ltd.'s (KOSDAQ:278280) 34% Jump Shows Its Popularity With InvestorsChunbo Co., Ltd. ( KOSDAQ:278280 ) shares have continued their recent momentum with a 34% gain in the last month alone...
Valuation Update With 7 Day Price Move • Oct 17Investor sentiment improves as stock rises 40%After last week's 40% share price gain to ₩59,600, the stock trades at a trailing P/E ratio of 42.7x. Average forward P/E is 11x in the Chemicals industry in South Korea. Total loss to shareholders of 72% over the past three years.
분석 기사 • Oct 16Returns On Capital Signal Tricky Times Ahead For Chunbo (KOSDAQ:278280)Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Ideally, a business...
New Risk • Oct 16New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.5x net interest cover). Earnings are forecast to decline by an average of 116% per year for the foreseeable future. Minor Risk Share price has been volatile over the past 3 months (7.7% average weekly change).
분석 기사 • Aug 27We Like Chunbo's (KOSDAQ:278280) Earnings For More Than Just Statutory ProfitChunbo Co., Ltd.'s ( KOSDAQ:278280 ) recent earnings report didn't offer any surprises, with the shares unchanged over...
New Risk • Aug 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.4x net interest cover). Earnings are forecast to decline by an average of 35% per year for the foreseeable future. Minor Risk Share price has been volatile over the past 3 months (7.8% average weekly change).
Major Estimate Revision • Aug 20Consensus revenue estimates decrease by 12%, EPS upgradedThe consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from ₩173.8m to ₩153.1m. EPS estimate increased from -₩736 to -₩678 per share. Chemicals industry in South Korea expected to see average net income growth of 35% next year. Consensus price target broadly unchanged at ₩59,143. Share price fell 8.9% to ₩44,600 over the past week.
분석 기사 • Jul 21Does Chunbo (KOSDAQ:278280) Have A Healthy Balance Sheet?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
분석 기사 • Jun 24After Leaping 30% Chunbo Co., Ltd. (KOSDAQ:278280) Shares Are Not Flying Under The RadarChunbo Co., Ltd. ( KOSDAQ:278280 ) shareholders would be excited to see that the share price has had a great month...
분석 기사 • May 30Returns On Capital At Chunbo (KOSDAQ:278280) Paint A Concerning PictureWhat are the early trends we should look for to identify a stock that could multiply in value over the long term...
New Risk • May 23New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 22% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.4x net interest cover). Earnings are forecast to decline by an average of 22% per year for the foreseeable future.
Major Estimate Revision • May 16Consensus EPS estimates fall by 205%The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -₩259 to -₩790 per share. Revenue forecast unchanged at ₩175.4m. Chemicals industry in South Korea expected to see average net income growth of 34% next year. Consensus price target broadly unchanged at ₩55,125. Share price rose 2.9% to ₩34,950 over the past week.
Major Estimate Revision • May 02Consensus EPS estimates fall by 545%, revenue upgradedThe consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast increased from ₩174.3m to ₩176.8m. Forecast EPS reduced from -₩40.19 to -₩259 per share. Chemicals industry in South Korea expected to see average net income growth of 35% next year. Consensus price target down from ₩57,875 to ₩55,375. Share price fell 3.8% to ₩35,750 over the past week.
Price Target Changed • May 01Price target decreased by 9.4% to ₩55,375Down from ₩61,125, the current price target is an average from 8 analysts. New target price is 53% above last closing price of ₩36,200. Stock is down 53% over the past year. The company is forecast to post a net loss per share of ₩259 next year compared to a net loss per share of ₩2,759 last year.
Major Estimate Revision • Apr 09Consensus revenue estimates decrease by 16%The consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from ₩207.8m to ₩174.3m. EPS estimate unchanged from -₩40.19 per share at last update. Chemicals industry in South Korea expected to see average net income growth of 31% next year. Consensus price target down from ₩65,375 to ₩63,857. Share price fell 7.3% to ₩30,300 over the past week.
Major Estimate Revision • Apr 03Consensus EPS estimates fall by 64%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from ₩207.8m to ₩189.6m. Losses expected to increase from ₩389 per share to ₩640. Chemicals industry in South Korea expected to see average net income growth of 31% next year. Consensus price target down from ₩65,375 to ₩61,125. Share price fell 11% to ₩31,500 over the past week.
Major Estimate Revision • Mar 21Consensus EPS estimates upgraded to ₩389 loss, revenue downgradedThe consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from ₩229.2m to ₩207.8m. 2025 losses expected to reduce from -₩542 to -₩389 per share. Chemicals industry in South Korea expected to see average net income growth of 28% next year. Consensus price target broadly unchanged at ₩66,444. Share price rose 3.1% to ₩37,800 over the past week.
Reported Earnings • Mar 13Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2024 results: ₩2,759 loss per share (improved from ₩4,205 loss in FY 2023). Revenue: ₩144.9b (down 21% from FY 2023). Net loss: ₩27.4b (loss narrowed 34% from FY 2023). Revenue missed analyst estimates by 6.6%. Earnings per share (EPS) exceeded analyst estimates by 46%. Revenue is forecast to grow 47% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Chemicals industry in South Korea. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 50 percentage points per year, which is a significant difference in performance.
공시 • Mar 06Chunbo Co., Ltd., Annual General Meeting, Mar 20, 2025Chunbo Co., Ltd., Annual General Meeting, Mar 20, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 312, jungwonsaneop-ro, judeok-eup, chungcheongbuk-do, chungju South Korea
공시 • Nov 30Chunbo Co., Ltd. announced that it has received KRW 200 billion in funding from a group of investorsOn November 29, 2024 Chunbo Co., Ltd. closed the transaction.
Major Estimate Revision • Nov 16Consensus EPS estimates upgraded to ₩5,074 loss, revenue downgradedThe consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from ₩173.9m to ₩157.3m. 2024 losses expected to reduce from -₩5,968 to -₩5,074 per share. Chemicals industry in South Korea expected to see average net income growth of 35% next year. Consensus price target down from ₩78,222 to ₩69,667. Share price fell 26% to ₩36,900 over the past week.
분석 기사 • Nov 13Why We're Not Concerned Yet About Chunbo Co., Ltd.'s (KOSDAQ:278280) 26% Share Price PlungeChunbo Co., Ltd. ( KOSDAQ:278280 ) shareholders that were waiting for something to happen have been dealt a blow with a...
Major Estimate Revision • Oct 15Consensus EPS estimates fall by 75%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from ₩177.7m to ₩173.9m. Losses expected to increase from ₩3,404 per share to ₩5,968. Chemicals industry in South Korea expected to see average net income growth of 55% next year. Consensus price target down from ₩80,778 to ₩78,222. Share price fell 9.3% to ₩58,500 over the past week.
Major Estimate Revision • Sep 05Consensus EPS estimates fall by 13%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from ₩181.7m to ₩175.9m. Losses expected to increase from ₩3,151 per share to ₩3,556. Chemicals industry in South Korea expected to see average net income growth of 63% next year. Consensus price target down from ₩83,000 to ₩80,778. Share price was steady at ₩58,700 over the past week.
Reported Earnings • Aug 16Second quarter 2024 earnings released: ₩2,196 loss per share (vs ₩3,107 loss in 2Q 2023)Second quarter 2024 results: ₩2,196 loss per share (improved from ₩3,107 loss in 2Q 2023). Revenue: ₩35.9b (down 24% from 2Q 2023). Net loss: ₩21.8b (loss narrowed 29% from 2Q 2023). Revenue is forecast to grow 35% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in South Korea. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 58 percentage points per year, which is a significant difference in performance.
분석 기사 • Aug 15What You Can Learn From Chunbo Co., Ltd.'s (KOSDAQ:278280) P/SChunbo Co., Ltd.'s ( KOSDAQ:278280 ) price-to-sales (or "P/S") ratio of 3.6x may look like a poor investment...
분석 기사 • Jul 16Would Chunbo (KOSDAQ:278280) Be Better Off With Less Debt?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Price Target Changed • Jun 21Price target decreased by 18% to ₩98,800Down from ₩119,917, the current price target is an average from 10 analysts. New target price is 36% above last closing price of ₩72,700. Stock is down 63% over the past year. The company is forecast to post a net loss per share of ₩3,408 next year compared to a net loss per share of ₩4,205 last year.
Major Estimate Revision • May 30Consensus revenue estimates decrease by 11%The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from ₩228.0m to ₩204.0m. EPS estimate unchanged from -₩3,544 per share at last update. Chemicals industry in South Korea expected to see average net income growth of 78% next year. Consensus price target down from ₩129,083 to ₩119,917. Share price fell 5.5% to ₩71,700 over the past week.
Price Target Changed • May 25Price target decreased by 7.9% to ₩123,250Down from ₩133,833, the current price target is an average from 12 analysts. New target price is 70% above last closing price of ₩72,700. Stock is down 61% over the past year. The company is forecast to post a net loss per share of ₩2,724 next year compared to a net loss per share of ₩4,205 last year.
분석 기사 • Apr 17Is Chunbo (KOSDAQ:278280) Using Too Much Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Reported Earnings • Mar 15Full year 2023 earnings released: ₩4,205 loss per share (vs ₩3,763 profit in FY 2022)Full year 2023 results: ₩4,205 loss per share (down from ₩3,763 profit in FY 2022). Revenue: ₩182.7b (down 44% from FY 2022). Net loss: ₩41.8b (down 212% from profit in FY 2022). Revenue is forecast to grow 45% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Chemicals industry in South Korea. Over the last 3 years on average, earnings per share has fallen by 57% per year but the company’s share price has only fallen by 19% per year, which means it has not declined as severely as earnings.
New Risk • Mar 15New major risk - Revenue and earnings growthEarnings have declined by 6.0% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.7x net interest cover). Earnings have declined by 6.0% per year over the past 5 years.
Price Target Changed • Feb 22Price target decreased by 8.6% to ₩143,538Down from ₩157,077, the current price target is an average from 13 analysts. New target price is 47% above last closing price of ₩97,700. Stock is down 58% over the past year. The company is forecast to post a net loss per share of ₩2,706 compared to earnings per share of ₩3,763 last year.
Upcoming Dividend • Dec 20Upcoming dividend of ₩500 per share at 0.4% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 10 April 2024. The company is not currently making a profit and is not cash flow positive. Trailing yield: 0.4%. Lower than top quartile of South Korean dividend payers (3.5%). Lower than average of industry peers (1.8%).
Price Target Changed • Nov 14Price target decreased by 8.4% to ₩199,083Down from ₩217,333, the current price target is an average from 12 analysts. New target price is 102% above last closing price of ₩98,500. Stock is down 62% over the past year. The company is forecast to post a net loss per share of ₩910 compared to earnings per share of ₩3,763 last year.
New Risk • Nov 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (16% operating cash flow to total debt). Minor Risk Share price has been volatile over the past 3 months (9.0% average weekly change).
Price Target Changed • Oct 24Price target decreased by 13% to ₩224,833Down from ₩258,583, the current price target is an average from 12 analysts. New target price is 102% above last closing price of ₩111,400. Stock is down 48% over the past year. The company is forecast to post earnings per share of ₩829 for next year compared to ₩3,763 last year.
Price Target Changed • Sep 02Price target decreased by 7.5% to ₩275,250Down from ₩297,545, the current price target is an average from 12 analysts. New target price is 85% above last closing price of ₩148,700. Stock is down 32% over the past year. The company is forecast to post earnings per share of ₩2,592 for next year compared to ₩3,763 last year.
Major Estimate Revision • Aug 17Consensus revenue estimates fall by 10%The consensus outlook for revenues in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from ₩299.0m to ₩267.7m. EPS estimate fell from ₩2,562 to ₩1,832 per share. Net income forecast to grow 17% next year vs 17% growth forecast for Chemicals industry in South Korea. Consensus price target down from ₩297,545 to ₩285,727. Share price fell 15% to ₩147,900 over the past week.
Valuation Update With 7 Day Price Move • Aug 16Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ₩138,500, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 13x in the Chemicals industry in South Korea. Total returns to shareholders of 11% over the past three years.
Major Estimate Revision • Jul 22Consensus EPS estimates fall by 16%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from ₩320.4m to ₩312.6m. EPS estimate also fell from ₩3,330 per share to ₩2,810 per share. Net income forecast to grow 51% next year vs 38% growth forecast for Chemicals industry in South Korea. Consensus price target of ₩297,545 unchanged from last update. Share price rose 6.1% to ₩198,000 over the past week.
Major Estimate Revision • May 02Consensus revenue estimates decrease by 27%The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from ₩432.8m to ₩317.6m. EPS estimate unchanged from ₩3,578 per share at last update. Chemicals industry in South Korea expected to see average net income growth of 23% next year. Consensus price target down from ₩326,636 to ₩317,545. Share price was steady at ₩193,700 over the past week.
Valuation Update With 7 Day Price Move • Apr 25Investor sentiment deteriorates as stock falls 23%After last week's 23% share price decline to ₩195,000, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 11x in the Chemicals industry in South Korea. Total returns to shareholders of 200% over the past three years.
Major Estimate Revision • Apr 13Consensus EPS estimates increase by 11%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has improved. 2023 revenue forecast increased from ₩407.0m to ₩432.8m. EPS estimate increased from ₩5,389 to ₩5,970 per share. Net income forecast to grow 65% next year vs 33% growth forecast for Chemicals industry in South Korea. Consensus price target up from ₩315,300 to ₩326,636. Share price rose 3.0% to ₩261,000 over the past week.
Major Estimate Revision • Mar 15Consensus revenue estimates fall by 20%The consensus outlook for revenues in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from ₩507.9m to ₩407.5m. EPS estimate fell from ₩7,701 to ₩4,928 per share. Net income forecast to grow 39% next year vs 30% growth forecast for Chemicals industry in South Korea. Consensus price target broadly unchanged at ₩315,300. Share price fell 14% to ₩226,500 over the past week.
Upcoming Dividend • Dec 21Upcoming dividend of ₩500 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 10 April 2023. Payout ratio is a comfortable 5.3% but the company is not cash flow positive. Trailing yield: 0.1%. Lower than top quartile of South Korean dividend payers (3.3%). Lower than average of industry peers (2.4%).
Price Target Changed • Sep 09Price target decreased to ₩360,000Down from ₩396,667, the current price target is an average from 9 analysts. New target price is 62% above last closing price of ₩222,900. Stock is down 16% over the past year. The company is forecast to post earnings per share of ₩4,791 for next year compared to ₩4,438 last year.
Valuation Update With 7 Day Price Move • May 19Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₩283,200, the stock trades at a forward P/E ratio of 50x. Average forward P/E is 12x in the Chemicals industry in South Korea. Total returns to shareholders of 283% over the past three years.
Reported Earnings • Mar 19Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2021 results: EPS: ₩4,438 (up from ₩2,767 in FY 2020). Revenue: ₩271.6b (up 75% from FY 2020). Net income: ₩43.8b (up 60% from FY 2020). Profit margin: 16% (down from 18% in FY 2020). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 2.5%. Earnings per share (EPS) missed analyst estimates by 100%. Over the next year, revenue is forecast to grow 45%, compared to a 19% growth forecast for the industry in South Korea. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 60% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Jan 27Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩262,500, the stock trades at a forward P/E ratio of 44x. Average forward P/E is 10x in the Chemicals industry in South Korea. Total returns to shareholders of 42% over the past year.
Upcoming Dividend • Dec 22Upcoming dividend of ₩300 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 11 April 2022. Payout ratio is a comfortable 7.5% but the company is not cash flow positive. Trailing yield: 0.1%. Lower than top quartile of South Korean dividend payers (2.4%). Lower than average of industry peers (1.4%).
Valuation Update With 7 Day Price Move • Sep 08Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₩265,500, the stock trades at a forward P/E ratio of 51x. Average forward P/E is 13x in the Chemicals industry in South Korea. Total returns to shareholders of 72% over the past year. Simply Wall St's valuation model estimates the intrinsic value at ₩137,141 per share.
Price Target Changed • Aug 22Price target increased to ₩296,429Up from ₩270,714, the current price target is an average from 7 analysts. New target price is 24% above last closing price of ₩238,900. Stock is up 63% over the past year.
Price Target Changed • Jul 20Price target increased to ₩266,429Up from ₩243,889, the current price target is an average from 7 analysts. New target price is 19% above last closing price of ₩223,100. Stock is up 137% over the past year.
Valuation Update With 7 Day Price Move • Jul 09Investor sentiment improved over the past weekAfter last week's 20% share price gain to ₩217,500, the stock trades at a forward P/E ratio of 47x. Average forward P/E is 11x in the Chemicals industry in South Korea. Total returns to shareholders of 119% over the past year. Simply Wall St's valuation model estimates the intrinsic value at ₩279,646 per share.
Price Target Changed • Jul 08Price target increased to ₩260,714Up from ₩237,222, the current price target is an average from 8 analysts. New target price is 27% above last closing price of ₩205,500. Stock is up 106% over the past year.
분석 기사 • Apr 14Is Chunbo (KOSDAQ:278280) Using Too Much Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
분석 기사 • Mar 16Does Chunbo (KOSDAQ:278280) Deserve A Spot On Your Watchlist?Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling...
Reported Earnings • Mar 11Full year 2020 earnings released: EPS ₩2,742 (vs ₩2,348 in FY 2019)The company reported a solid full year result with improved earnings and revenues, although profit margins were flat. Full year 2020 results: Revenue: ₩155.5b (up 15% from FY 2019). Net income: ₩27.3b (up 19% from FY 2019). Profit margin: 18% (in line with FY 2019).
분석 기사 • Mar 02Is It Time To Consider Buying Chunbo Co., Ltd. (KOSDAQ:278280)?While Chunbo Co., Ltd. ( KOSDAQ:278280 ) might not be the most widely known stock at the moment, it saw significant...
Is New 90 Day High Low • Feb 26New 90-day low: ₩160,200The company is down 11% from its price of ₩180,300 on 27 November 2020. The South Korean market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩139,545 per share.
분석 기사 • Feb 17Has Chunbo (KOSDAQ:278280) Got What It Takes To Become A Multi-Bagger?What trends should we look for it we want to identify stocks that can multiply in value over the long term? Firstly...
분석 기사 • Feb 02Should We Be Delighted With Chunbo Co., Ltd.'s (KOSDAQ:278280) ROE Of 11%?Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
분석 기사 • Jan 18Introducing Chunbo (KOSDAQ:278280), The Stock That Zoomed 166% In The Last YearChunbo Co., Ltd. ( KOSDAQ:278280 ) shareholders might be concerned after seeing the share price drop 10% in the last...
Price Target Changed • Jan 07Price target raised to ₩204,250Up from ₩184,400, the current price target is an average from 8 analysts. The new target price is 8.1% above the current share price of ₩189,000. As of last close, the stock is up 194% over the past year.
Is New 90 Day High Low • Jan 04New 90-day high: ₩191,700The company is up 13% from its price of ₩169,100 on 06 October 2020. The South Korean market is up 21% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 22% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩139,908 per share.
분석 기사 • Dec 31Is Chunbo Co., Ltd. (KOSDAQ:278280) Worth ₩182k Based On Its Intrinsic Value?Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Chunbo Co., Ltd...
분석 기사 • Dec 16Here's Why We Don't Think Chunbo's (KOSDAQ:278280) Statutory Earnings Reflect Its Underlying Earnings PotentialBroadly speaking, profitable businesses are less risky than unprofitable ones. However, sometimes companies receive a...
Price Target Changed • Dec 15Price target raised to ₩184,400Up from ₩154,333, the current price target is an average from 11 analysts. The new target price is 7.8% above the current share price of ₩171,000. As of last close, the stock is up 215% over the past year.
분석 기사 • Dec 02Is Chunbo (KOSDAQ:278280) A Risky Investment?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
분석 기사 • Nov 18Will Chunbo (KOSDAQ:278280) Multiply In Value Going Forward?What trends should we look for it we want to identify stocks that can multiply in value over the long term? Firstly...
Valuation Update With 7 Day Price Move • Nov 03Market bids up stock over the past weekAfter last week's 18% share price gain to ₩164,400, the stock is trading at a trailing P/E ratio of 74.6x, up from the previous P/E ratio of 63.2x. This compares to an average P/E of 12x in the Chemicals industry in South Korea. Total returns to shareholders over the past year are 155%.